GIP and type 2 diabetes mellitus: A recent study by Pirro and colleagues [63] demonstrated that tirzepatide, a dual GIP and GLP-1 receptor agonist that improves glycemic control in T2D patients, was also shown to markedly lower plasma BCAAs.